美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物科技指數ETF-iShares Nasdaq

202.00

-2.5888-1.27%

盤後：202.000.00000.00%19:30 EDT

成交量：191.71萬

成交額：3.87億

市值：102.92億

市盈率：32.00

高：204.18

開：203.82

低：200.52

收：204.59

52周最高：217.12

52周最低：138.79

股本：5,095.00萬

流通股本：5,095.00萬

量比：1.14

換手率：3.76%

股息：0.41

股息率：0.20%

每股收益(TTM):6.31

每股收益(LYR):35.34

淨資產收益率：24.54%

總資產收益率：0.10%

市淨率：1.26

市盈率(LYR):5.72

資料載入中...

總覽公司新聞資訊公告

百時美施貴寶就奧普迪沃擬推出的生物類似藥起訴安進

吉利德科學攜手巴西衞生部，共促Lenacapavir本地化生產新篇章

吉利德科學：持續探索與泛美衞生組織合作，助力各國準備好並擴大長效艾滋病預防措施的普及

吉利德科學公司高管在電話會議上表示，HIV藥物市場的增長預計將在未來幾個季度內迴歸至2%至3%的正常水平。

吉利德與泛美衞生組織就拉丁美洲和加勒比地區艾滋病預防藥物獲取問題達成一致

吉利德科學攜手泛美衞生組織，加速拉美及加勒比地區HIV預防藥物Lenacapavir的可及性

吉利德高管表示，未來幾個季度HIV市場增長或將回歸2%-3%常態水平

吉利德高管透露：周服HIV預防藥物有望2027年第一季度上市

對外授權交易總額約1100億美元！2026年上半年創新藥「出海」觀察：多款獲批生物類似藥寄望海外收入超越國內

每日经济新闻

松江奇蹟：一家中國藥企的「體系化出海」豪賭｜未來企業調研行

华夏时报网

阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。

復星醫藥(600196.SH)子公司地舒單抗生物類似藥HLX14註冊申請獲受理

又爆了！集體飆漲！中東，再傳重磅

對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥

對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥

全球118款生物藥即將失去專利或獨佔權，生物類似藥的「潑天富貴」來了？

安進（AMGN）聯合療法III期臨床達主要終點

安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率

市場風向標：安進股價遭受重創

Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/IBB/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","market":"US","secType":"STK","nameCN":"生物科技指數ETF-iShares Nasdaq","latestPrice":202,"timestamp":1789502400000,"preClose":204.5888,"halted":0,"volume":1917143,"hourTrading":{"tag":"盘后","latestPrice":202,"preClose":202,"latestTime":"19:30 EDT","volume":4798,"amount":969211.88138,"timestamp":1789515007017,"change":0,"changeRate":0,"amplitude":0.005446},"delay":0,"changeRate":-0.012653674101417049,"floatShares":50950000,"shares":50950000,"eps":6.311863,"marketStatus":"盤後交易","change":-2.5888,"latestTime":"09-15 19:36:44 EDT","open":203.82,"high":204.18,"low":200.52,"amount":387171169.87887996,"amplitude":0.01789,"askPrice":203.1,"askSize":1500,"bidPrice":202,"bidSize":310,"shortable":3,"etf":1,"ttmEps":6.311863,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1789516800000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":204.5888,"sharesOutstanding":49450000,"nav":202.867176,"aum":10356369334.8,"dividendRate":0.002006,"bidAskSpread":0.000338,"preHourTrading":{"tag":"盘前","latestPrice":203.56,"preClose":204.5888,"latestTime":"07:51 EDT","volume":104,"amount":21178.00568,"timestamp":1789473086311,"change":-1.0288,"changeRate":-0.005029,"amplitude":0.02326},"postHourTrading":{"tag":"盘后","latestPrice":202,"preClose":202,"latestTime":"19:30 EDT","volume":4798,"amount":969211.88138,"timestamp":1789515007017,"change":0,"changeRate":0,"amplitude":0.005446},"volumeRatio":1.137102,"impliedVol":0.2306,"impliedVolPercentile":0.4622},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBB\",,,,,undefined,":{"symbol":"IBB","floatShares":50950000,"roa":"0.10%","roe":"24.54%","lyrEps":35.344796,"volumeRatio":1.137102,"shares":50950000,"dividePrice":0.4053,"high":204.18,"amplitude":0.01789,"preClose":204.5888,"low":200.52,"week52Low":138.785,"pbRate":"1.26","psRate":"247.61","week52High":217.12,"institutionHeld":0,"latestPrice":202,"committee":-0.657459,"eps":6.311863,"divideRate":0.002006,"volume":1917143,"delay":0,"ttmEps":6.311863,"open":203.82,"prevYearClose":168.77,"prevWeekClose":202.93,"prevMonthClose":209.05,"prevQuarterClose":190.19,"fiveDayClose":207.33,"twentyDayClose":201.93,"sixtyDayClose":173.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBB\",params:#limit:5,,,undefined,":[{"date":"2026-09-15","symbol":"IBB","amount":0.011194,"announcedDate":"2026-09-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-18","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-18"},{"date":"2026-06-15","symbol":"IBB","amount":0.023774,"announcedDate":"2026-06-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2026-03-17","symbol":"IBB","amount":0.121818,"announcedDate":"2026-03-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-17","defaultRemindTime":1773754200000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-20","payableDate":"2026-03-17","currency":"USD","dateTimestamp":1773720000000,"payDate":"2026-03-20"},{"date":"2025-12-16","symbol":"IBB","amount":0.183099,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2025-09-16","symbol":"IBB","amount":0.082843,"announcedDate":"2025-09-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-16","defaultRemindTime":1758029400000,"name":"生物科技指数ETF-iShares Nasdaq","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-19","payableDate":"2025-09-16","currency":"USD","dateTimestamp":1757995200000,"payDate":"2025-09-19"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBB\",market:\"US\",,,undefined,":[{"executeDate":"2016-09-26","recordDate":"2016-09-28","paymentDate":"2016-09-30","value":0.0858219,"currency":"USD"},{"executeDate":"2016-12-22","recordDate":"2016-12-27","paymentDate":"2016-12-29","value":0.091903,"currency":"USD"},{"executeDate":"2017-03-24","recordDate":"2017-03-28","paymentDate":"2017-03-30","value":0.29898,"currency":"USD"},{"executeDate":"2017-06-27","recordDate":"2017-06-29","paymentDate":"2017-06-30","value":0.176803,"currency":"USD"},{"executeDate":"2017-09-26","recordDate":"2017-09-27","paymentDate":"2017-09-29","value":0.118654,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBB\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667629132","title":"百時美施貴寶就奧普迪沃擬推出的生物類似藥起訴安進","url":"https://stock-news.laohu8.com/highlight/detail?id=2667629132","media":"路透中文","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667629132?lang=zh_tw&edition=fundamental","pubTime":"2026-09-16 01:29","pubTimestamp":1789493363,"startTime":"0","endTime":"0","summary":"百时美施贵宝就奥普迪沃拟推出的生物类似药起诉安进Blake Brittain路透9月15日-百时美施贵宝公司和小野制药公司已在特拉华州联邦法院起诉安进公司，试图阻止安进公司在美国推出其畅销癌症免疫疗法药物“欧迪沃”的生物类似药。百时美施贵宝和小野制药的发言人尚未立即回应置评请求。共同开发“欧狄沃”的百时美施贵宝和小野制药指控，安进的生物类似药将侵犯该药物所涉及的七项美国专利，并请求法院在专利有效期内禁止该生物类似药的销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4T4571DK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","PBE","BK4585","AMGN","LU1670711040.USD","LU0432979614.USD","LU0320765992.SGD","IBB","LU1989771016.USD","LU0456855351.SGD","LU0889565916.HKD","LU0225284248.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","PJP","LU1074936037.SGD","LU2468319806.SGD","IE0002141913.USD","BK4139","BK4533","BK4559","LU2242646821.SGD","04332","LU1093756325.SGD","LU1868836757.USD","LU2089984988.USD","BK4534","BK4588","LU1571399168.USD","BMY","LU0289739699.SGD","IE00BFXG1179.USD","IE00BSNM7G36.USD","BK4007","LU2133065610.SGD","LU0306807586.USD","LU0321505868.SGD","LU0096364046.USD","LU0321505439.SGD","LU0109394709.USD","LU1670710661.SGD","BK4532","LU0237698245.USD","LU0114720955.EUR","LU1236620750.USD","LU1585245621.USD","LU0882574055.USD","LU0225771236.USD","LU1291159041.SGD","BK4581","LU1093756168.USD","LU1236620834.HKD","LU0306806265.USD","LU1032466523.USD","LU1868837300.USD","LU0061475181.USD","LU1718418525.SGD","LU0122379950.USD","LU2360032135.SGD","LU1868836591.USD","LU1261432733.SGD","LU2125154935.USD","LU1057294990.SGD","LU0985481810.HKD","BIB","LU0058720904.USD","IE00B2B36J28.USD","IBBQ","LU2596442595.SGD","LU0267386448.USD","LU1023059063.AUD","LU2125154778.USD","LU1670710588.SGD","LU2242652126.USD","LU1061106388.HKD","LU1323610961.USD","IE00BFTCPJ56.SGD","LU1868836914.USD","LU1883839398.USD","IE00BJT1NW94.SGD","LU1868837136.USD","LU1430594728.SGD","LU1670711123.USD","BBH","FTXH","SG9999001440.SGD","IE0009355771.USD","LU2112291526.USD","LU0868494617.USD","BK4566","TBXU","LU1983299246.USD","IHE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120765496","title":"吉利德科學攜手巴西衞生部，共促Lenacapavir本地化生產新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=1120765496","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120765496?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485331,"startTime":"0","endTime":"0","summary":"吉利德科学公司近日透露，正积极与巴西卫生部探索合作良机，旨在助力该国实现Lenacapavir药物的本土生产愿景。这一举措，无疑为巴西医药产业自主化进程注入了强劲动力。据悉，双方的洽谈聚焦于如何深化协作，以切实推进巴西卫生部既定的战略目标——即构建并强化Lenacapavir的本地制造能力。Lenacapavir，作为一款备受瞩目的长效抗逆转录病毒药物，其本地化生产若能落地，对巴西乃至更广泛地区的HIV防治工作意义深远。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","LU0114720955.EUR","IE00BSNM7G36.USD","BK4139","BK4583","LU1023059063.AUD","LU0289739699.SGD","LU0965509283.SGD","LU1066051498.USD","LU1778281490.HKD","LU0859254822.USD","LU1430594728.SGD","MEDI","LU0320765992.SGD","LU0965509101.SGD","LU2357627491.SGD","SG9999015986.USD","IE00B19Z3581.USD","IE00B3T34201.USD","LU2089984988.USD","BBH","LU2468319806.SGD","GILD","BK4568","LU0122379950.USD","SG9999015945.SGD","IE00B19Z3B42.SGD","LU1057294990.SGD","BK4585","BK4588","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1674673428.USD","LU1934455277.USD","LU1585245621.USD","LU0109394709.USD","BK4550","LU0058720904.USD","LU0882574055.USD","LU1934455863.HKD","TMED","LU1061106388.HKD","LU1934455194.USD","LU0965508806.USD","TBXU","LU1674673691.USD","BK4566","LU1066053197.SGD","LU1037948897.HKD","LU0234570918.USD","LU0965509010.AUD","LU0823416689.USD","LU1037948541.HKD","IBBQ","BIB","LU0889565916.HKD","LU1839511570.USD","SG9999015952.SGD","BK4532","BMED","IE00B7SZLL34.SGD","LU0861579265.USD","SG9999015978.USD","LU2087621335.USD","BK4578","IE0002270589.USD","LU2112291526.USD","LU2324357040.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158863992","title":"吉利德科學：持續探索與泛美衞生組織合作，助力各國準備好並擴大長效艾滋病預防措施的普及","url":"https://stock-news.laohu8.com/highlight/detail?id=1158863992","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158863992?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:15","pubTimestamp":1789485330,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）宣布，将继续探索与泛美卫生组织（PAHO）的合作机会，以支持各国做好充分准备，并推动长效艾滋病预防手段的可及性扩展。这一举措旨在强化全球公共卫生应对体系，尤其是针对中低收入国家的需求，通过技术转移、能力建设及供应链优化等途径，加快长效预防方案的落地与规模化应用。双方的合作重点在于应对实施层面的挑战，确保相关资源能够高效、公平地分配至最需要的人群，从而在更大范围内遏制HIV的传播。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","BK4550","LU0823416689.USD","IE00B3T34201.USD","LU1430594728.SGD","SG9999015945.SGD","BBH","BK4139","BK4588","LU0109394709.USD","LU0320765992.SGD","LU1571399168.USD","IBBQ","LU0965509283.SGD","LU1585245621.USD","MEDI","LU2089984988.USD","BK4578","SG9999015986.USD","LU1066051498.USD","LU1839511570.USD","BK4583","LU0122379950.USD","LU2324357040.USD","LU1674673428.USD","SG9999015978.USD","LU0859254822.USD","LU0882574055.USD","LU0965509010.AUD","LU1057294990.SGD","LU1061106388.HKD","LU2468319806.SGD","LU2112291526.USD","BK4532","LU0965509101.SGD","BMED","LU1934455194.USD","LU1037948541.HKD","LU2357627491.SGD","IBB","LU1674673691.USD","BK4585","TBXU","LU0861579265.USD","LU0234570918.USD","IE00B7SZLL34.SGD","LU0114720955.EUR","LU1037948897.HKD","LU1934455277.USD","BK4568","LU0889565916.HKD","IE00BKVL7J92.USD","LU1066053197.SGD","LU2087621335.USD","LU1934455863.HKD","SG9999015952.SGD","IE00B19Z3B42.SGD","LU1023059063.AUD","BIB","IE0002270589.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","TMED","LU0058720904.USD","IE00BSNM7G36.USD","GILD","BK4566","LU0965508806.USD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667623020","title":"吉利德科學公司高管在電話會議上表示，HIV藥物市場的增長預計將在未來幾個季度內迴歸至2%至3%的正常水平。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667623020","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667623020?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:11","pubTimestamp":1789485099,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0859254822.USD","IE0002270589.USD","TBXU","BK4550","LU1057294990.SGD","LU1066051498.USD","LU1839511570.USD","IBBQ","LU0234570918.USD","LU0965509283.SGD","LU0122379950.USD","IE00B19Z3B42.SGD","LU2112291526.USD","SG9999015978.USD","IE00B19Z3581.USD","LU0889565916.HKD","LU1934455277.USD","BK4532","LU2324357040.USD","LU0289739699.SGD","BMED","BK4566","IBB","BK4568","LU0965509101.SGD","BIB","LU1066053197.SGD","BK4139","GILD","LU1037948897.HKD","LU1585245621.USD","LU1674673691.USD","LU0320765992.SGD","LU0882574055.USD","LU0058720904.USD","LU1674673428.USD","TMED","LU0114720955.EUR","SG9999015952.SGD","LU1061106388.HKD","LU1037948541.HKD","SG9999015945.SGD","LU0965509010.AUD","BK4588","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","MEDI","BBH","LU1430594728.SGD","LU1934455863.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667062306","title":"吉利德與泛美衞生組織就拉丁美洲和加勒比地區艾滋病預防藥物獲取問題達成一致","url":"https://stock-news.laohu8.com/highlight/detail?id=2667062306","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667062306?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485029,"startTime":"0","endTime":"0","summary":"吉利德与泛美卫生组织就拉丁美洲和加勒比地区艾滋病预防药物获取问题达成一致路透9月15日-美国制药公司吉利德科学GILD.O周二表示，已与泛美卫生组织达成协议，将在拉丁美洲和加勒比地区扩大其艾滋病预防药物的可及性，以帮助这些地区遏制新发感染。吉利德公司指出，2010年至2024年间，拉丁美洲和加勒比地区的新发艾滋病毒感染病例增加了13%，并归因于艾滋病毒预防药物使用方面的缺口。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260915:nL4T45714A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1061106388.HKD","BK4568","LU2324357040.USD","MEDI","BK4139","LU0965509010.AUD","LU1057294990.SGD","BK4550","IE00B19Z3B42.SGD","LU0114720955.EUR","LU1585245621.USD","TBXU","LU1066051498.USD","BBH","IE00BKVL7J92.USD","LU0058720904.USD","IE0002270589.USD","IBB","LU1037948897.HKD","LU0859254822.USD","SG9999015945.SGD","LU0122379950.USD","SG9999015952.SGD","LU1934455277.USD","SG9999015978.USD","LU0965509101.SGD","LU2112291526.USD","LU0965509283.SGD","LU0889565916.HKD","LU1934455863.HKD","LU0320765992.SGD","IBBQ","TMED","LU1674673691.USD","BMED","IE00B19Z3581.USD","BK4588","LU1037948541.HKD","LU1839511570.USD","BIB","LU0882574055.USD","LU1066053197.SGD","GILD","BK4532","LU0234570918.USD","LU1674673428.USD","IE00B7SZLL34.SGD","LU1430594728.SGD","LU0289739699.SGD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159280995","title":"吉利德科學攜手泛美衞生組織，加速拉美及加勒比地區HIV預防藥物Lenacapavir的可及性","url":"https://stock-news.laohu8.com/highlight/detail?id=1159280995","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159280995?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:10","pubTimestamp":1789485009,"startTime":"0","endTime":"0","summary":"吉利德科学（Gilead Sciences）日前宣布，与泛美卫生组织（PAHO）达成一项战略合作。此番联手，旨在显著提升一年两针的HIV预防药物Lenacapavir在拉丁美洲及加勒比地区的可及性。双方的合作，将为该区域的高风险人群带来更便捷的预防选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","LU2324357040.USD","LU0114720955.EUR","MEDI","SG9999015978.USD","LU1430594728.SGD","BIB","IE00B19Z3581.USD","LU1839511570.USD","GILD","LU2089984988.USD","LU1037948541.HKD","LU0965509101.SGD","LU0289739699.SGD","LU2112291526.USD","BK4566","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","IBBQ","LU1037948897.HKD","BK4578","SG9999015986.USD","LU0965508806.USD","LU2468319806.SGD","LU2087621335.USD","LU2357627491.SGD","BK4139","LU1023059063.AUD","LU0320765992.SGD","LU0882574055.USD","LU1934455277.USD","LU0861579265.USD","IE00BSNM7G36.USD","LU1585245621.USD","LU0122379950.USD","LU0234570918.USD","LU1778281490.HKD","BK4568","LU0889565916.HKD","LU0058720904.USD","LU1674673691.USD","BK4550","LU1061106388.HKD","LU1571399168.USD","BMED","LU1066053197.SGD","IE00B3T34201.USD","IE0002270589.USD","BBH","IE00BKVL7J92.USD","LU1934455863.HKD","BK4585","TBXU","TMED","IE00B19Z3B42.SGD","LU0965509283.SGD","LU0109394709.USD","LU0823416689.USD","LU1057294990.SGD","LU0859254822.USD","SG9999015945.SGD","BK4588","LU1674673428.USD","LU1934455194.USD","IBB","BK4532","LU0965509010.AUD","SG9999015952.SGD","LU1066051498.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153389014","title":"吉利德高管表示，未來幾個季度HIV市場增長或將回歸2%-3%常態水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1153389014","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153389014?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:09","pubTimestamp":1789484948,"startTime":"0","endTime":"0","summary":"吉利德高管在电话会议中透露，该公司预计HIV治疗市场的增长势头将在未来几个季度内逐步趋于稳定，最终回到2%至3%的年增长区间。这一表态正值市场对HIV药物需求持续波动的关键节点。高管指出，当前的增长水平仍高于长期趋势，但随着时间推移，这种偏热的状态将逐渐降温。整个行业的扩张速度，预计将在近期内回落至更为可持续的轨道上。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0859254822.USD","LU0965509283.SGD","IE00B19Z3B42.SGD","IBB","IE00B19Z3581.USD","LU0965509101.SGD","BBH","BK4585","LU1778281490.HKD","BIB","LU1037948897.HKD","SG9999015945.SGD","BK4583","IE00BZ1G4Q59.USD","LU1037948541.HKD","LU1430594728.SGD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU1674673428.USD","TBXU","LU2324357040.USD","LU1839511570.USD","LU1934455277.USD","BK4139","BK4568","LU1023059063.AUD","SG9999015986.USD","LU0234570918.USD","BK4588","IE00B3T34201.USD","BK4578","LU1934455194.USD","MEDI","LU2112291526.USD","SG9999015978.USD","SG9999015952.SGD","BMED","LU0122379950.USD","LU0109394709.USD","LU1061106388.HKD","LU1066051498.USD","LU0058720904.USD","LU0861579265.USD","LU2089984988.USD","LU0965508806.USD","TMED","LU1585245621.USD","GILD","IE0002270589.USD","LU0882574055.USD","LU0289739699.SGD","LU0114720955.EUR","BK4532","IE00B7SZLL34.SGD","BK4566","LU2087621335.USD","LU0965509010.AUD","LU1674673691.USD","LU1066053197.SGD","LU0320765992.SGD","LU0889565916.HKD","LU1934455863.HKD","LU0823416689.USD","LU1057294990.SGD","LU2468319806.SGD","LU2357627491.SGD","BK4550","LU1571399168.USD","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131138631","title":"吉利德高管透露：周服HIV預防藥物有望2027年第一季度上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1131138631","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131138631?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 23:05","pubTimestamp":1789484737,"startTime":"0","endTime":"0","summary":"吉利德科学高管在电话会议中表示，其每周口服HIV预防药物预计将于2027年第一季度正式推出。这一表态为公司抗艾药物管线注入了新的期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD","LU0058720904.USD","BK4139","BIB","LU0965509283.SGD","TBXU","LU2324357040.USD","BK4550","IE00BSNM7G36.USD","LU0114720955.EUR","LU0234570918.USD","LU0289739699.SGD","LU1571399168.USD","IE00B7SZLL34.SGD","LU1066051498.USD","LU1037948541.HKD","LU0122379950.USD","LU1430594728.SGD","SG9999015986.USD","LU1061106388.HKD","LU0965508806.USD","LU2357627491.SGD","BK4578","BK4566","IE00B19Z3B42.SGD","LU0109394709.USD","LU1585245621.USD","SG9999015978.USD","BBH","LU1674673691.USD","LU1023059063.AUD","LU1066053197.SGD","LU0889565916.HKD","LU1934455277.USD","IE00BKVL7J92.USD","LU2089984988.USD","BK4532","BK4568","LU0320765992.SGD","LU1057294990.SGD","LU0861579265.USD","LU1934455194.USD","IE00B3T34201.USD","LU0823416689.USD","IBB","LU1674673428.USD","LU1934455863.HKD","BK4588","IE00B19Z3581.USD","LU2087621335.USD","LU2112291526.USD","LU2468319806.SGD","SG9999015952.SGD","BMED","IE0002270589.USD","LU1037948897.HKD","IBBQ","LU0882574055.USD","LU0965509010.AUD","SG9999015945.SGD","TMED","BK4585","BK4583","LU1839511570.USD","MEDI","LU1778281490.HKD","IE00BZ1G4Q59.USD","LU0965509101.SGD","LU0859254822.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667660668","title":"對外授權交易總額約1100億美元！2026年上半年創新藥「出海」觀察：多款獲批生物類似藥寄望海外收入超越國內","url":"https://stock-news.laohu8.com/highlight/detail?id=2667660668","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667660668?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 01:03","pubTimestamp":1789405401,"startTime":"0","endTime":"0","summary":"2026年上半年，中国创新药延续高增长态势。国家药监局数据显示，2026年1~6月，中国创新药对外授权交易共81笔，总额约1100亿美元，已达2025年全年总额的八成，创历史新高。《每日经济新闻》记者（以下简称每经记者）注意到，从上市公司半年报来看，首付款作为部分企业BD（商务拓展）收入的一部分，让利润表短暂“翻红”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609153873800338.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609153873800338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","MEDX","IE00B5TLWC47.USD","LU2272731865.HKD","06978","LU1992135472.HKD","IBBQ","BK1161","BK4588","LU2272731782.SGD","PPH","LU2322448957.HKD","159992","LU2272731600.USD","LU2473716301.USD","LU2322448791.USD","LU1992135399.USD","XPH","IBB","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666503466","title":"松江奇蹟：一家中國藥企的「體系化出海」豪賭 ｜ 未來企業調研行","url":"https://stock-news.laohu8.com/highlight/detail?id=2666503466","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666503466?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 12:14","pubTimestamp":1789186482,"startTime":"0","endTime":"0","summary":"编者按：9月的一天，《华夏时报》未来企业竞争力调研团队来到位于上海松江的复宏汉霖全球生产基地——中国生物制药版图上，一处正在悄悄改写规则的所在。这家中国生物药企拒绝只卖“青苗”，而是试图用生物类似药的现金流，搭建从临床、报批到商业化的全球闭环。但真正的考验在于：创新药管线能否在专利悬崖窗口期兑现为第二增长曲线。上海松江，文俊路618弄。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609123872706781.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609123872706781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2272731782.SGD","LU1992135399.USD","IE00B5TLWC47.USD","LU2473716301.USD","IBB","LU2272731865.HKD","BK4135","LU2322448791.USD","LU2272731600.USD","LU1992135472.HKD","PPH","XPH","LU2322448957.HKD","BCG","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股價盤後跌超2%，因其三期臨床試驗結果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666571008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FBT","HELX","IDNA","RXL","LU2272731600.USD","AZNH","BME","IEHS","BK4585","LU2473716301.USD","IEIH","PPH","LU2272731782.SGD","XBIX","LU2322448791.USD","SYNB","LU2322448957.HKD","LU1992135472.HKD","PJP","MRNY","LU2272731865.HKD","MEDI","IBRN","RSPH","PBE","TMED","GNOM","PBPH","BBP","IBB","BBH","CANC","BK4588","BIB","XPH","BIOY","FTXH","MRNX","IE00B5TLWC47.USD","SBIO","LFSC","PSCH","LU1992135399.USD","WDNA","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666235705","title":"復星醫藥(600196.SH)子公司地舒單抗生物類似藥HLX14註冊申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666235705","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666235705?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 17:44","pubTimestamp":1789119840,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药 发布公告，近日，公司控股子公司上海复宏汉霖生物技术股份有限公司及其控股子公司自主研发的地舒单抗生物类似药HLX14120mg/瓶规格的药品注册申请获国家药品监督管理局受理。此次申报适应症为其参照药安加维于中国境内已获批上市的所有适应症。据悉，HLX14为公司自主研发的地舒单抗生物类似药。截至公告日期，HLX14已分别于美国、欧盟、英国、加拿大获批上市。截至2026年8月，公司现阶段针对HLX14的累计研发投入约为3.52亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495051.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2272731782.SGD","PPH","BK0183","BK0060","LU1992135399.USD","LU2322448957.HKD","BK0188","BK1191","LU2272731600.USD","BK1515","BK4585","BK0239","BK0096","600196","02196","IBB","BK0187","BK0028","BK1593","LU2473716301.USD","BK0175","LU1992135472.HKD","XPH","LU2322448791.USD","LU2272731865.HKD","IE00B5TLWC47.USD","BK0196","BK4588","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666528665","title":"又爆了！集體飆漲！中東，再傳重磅","url":"https://stock-news.laohu8.com/highlight/detail?id=2666528665","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666528665?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 11:37","pubTimestamp":1789011420,"startTime":"0","endTime":"0","summary":"中午好，在本周二大涨之后，能化板块又爆发了！周四早盘，原油期货主力合约一度涨近10%，纯苯、苯乙烯期货主力合约涨停。截至11:30收盘，原油期货主力合约涨幅有所收窄，纯苯期货主力合约涨 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260910/c679776426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["BK4139","BK4599","LU2089984988.USD","IBBQ","LU2112291526.USD","BK4566","LU0889565916.HKD","BK4534","LU2468319806.SGD","IE0002141913.USD","LU1057294990.SGD","LU0289739699.SGD","LU0122379950.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU1571399168.USD","BK4581","BK4588","IE0009355771.USD","LU0320765992.SGD","LU0868494617.USD","IE00B2B36J28.USD","BK4585","IE00BJJMRZ35.SGD","TBXU","LU2242646821.SGD","LU1983299246.USD","LU2242652126.USD","BK4533","LU0109394709.USD","PJP","IBB","BBH","SG9999001440.SGD","IE00B4R5TH58.HKD","BIB","LU1023059063.AUD","LU0058720904.USD","AMGN","PBE","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666356195","title":"對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2666356195","media":"新浪科技","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666356195?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 21:04","pubTimestamp":1788959040,"startTime":"0","endTime":"0","summary":"新浪科技讯 9月9日晚间消息，在2026亚布力论坛夏季年会期间，在与新浪科技的对话中，复宏汉霖执行董事、首席执行官朱俊博士系统阐释了公司“体系出海”战略的底层逻辑。另一种是复宏汉霖坚持的“体系出海”，最终目的是拿到“长线收益”。营收方面，朱俊表示公司上半年实现营收35.88亿元，其中海外收入占比达19%，海外产品销售收入同比大幅提升159.4%至1.05亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-09/doc-inirfumn8933987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000306701.USD","BK1161","LU1992135399.USD","HK0000320264.USD","06978","LNGR","HK0000306685.HKD","HK0000165453.HKD","IE00B5TLWC47.USD","BK1574","LU2272731600.USD","PPH","XPH","HK0000320223.HKD","BK4585","LU2322448957.HKD","LU2272731782.SGD","02696","MEDX","159992","BK4588","IBBQ","IBB","LU2322448791.USD","LU2473716301.USD","LU1992135472.HKD","LU2272731865.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666533226","title":"對話復宏漢霖朱儁：體系出海要拿「長線收益」，2030年創新藥收入將反超生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2666533226","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666533226?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:54","pubTimestamp":1788958467,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2473716301.USD","LNGR","IBBQ","PPH","IBB","LU1992135472.HKD","LU2272731865.HKD","BK4585","LU1992135399.USD","LU2272731600.USD","XPH","BK4588","LU2272731782.SGD","LU2322448957.HKD","MEDX","LU2322448791.USD","IE00B5TLWC47.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666580032","title":"全球118款生物藥即將失去專利或獨佔權，生物類似藥的「潑天富貴」來了？","url":"https://stock-news.laohu8.com/highlight/detail?id=2666580032","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666580032?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:42","pubTimestamp":1788954152,"startTime":"0","endTime":"0","summary":"中国市场中生物类似药面临集采降价的潜在压力，而市场的增长潜力在哪？9月8日，在复宏汉霖开放日活动上，波士顿咨询公司（BCG）合伙人杜菁表示，全球正迎来生物类似药发展的重大窗口期，重磅原研药集中进入专利悬崖，叠加欧美政策持续利好，预计2035年全球生物类似药市场规模将突破2400亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093869495082.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093869495082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2322448957.HKD","159839","PPH","LU2272731600.USD","BK4588","IE00B5TLWC47.USD","XPH","BK4585","LU1992135399.USD","LU2272731782.SGD","IBB","LU2272731865.HKD","LU2473716301.USD","LU2322448791.USD","LU1992135472.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666712586","title":"安進（AMGN）聯合療法III期臨床達主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2666712586","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666712586?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:59","pubTimestamp":1788944360,"startTime":"0","endTime":"0","summary":"金吾财经 | 安进公布，双特异性T细胞衔接器Imdelltra联合阿斯利康PD-L1抑制剂英飞凡，在广泛期小细胞肺癌的后期临床试验中实现总生存期延长。这家加州生物制药企业披露III期DeLLphi-305研究中期数据，该试验达成广泛期小细胞肺癌患者总生存期主要终点。该项全球试验评估该组合作为一线维持治疗，受试者既往接受过包含英飞凡的治疗且病情未发生进展。研究同时达成无进展生存期、客观缓解率两项次要终点。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjNkZWQ4NGZiN2I3MDYxNDlhOTlmZGM4ZTUwODkzNDUzNTE2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","AMGN","BK4566","LU0109394709.USD","LU2468319806.SGD","LU2237443978.SGD","LU2112291526.USD","LU2237443895.HKD","BK4581","BIB","AZNH","PJP","LU0889565916.HKD","IE0002141913.USD","LU0128525929.USD","LU0122379950.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","BBH","IE00B4R5TH58.HKD","LU1571399168.USD","BK4533","LU1023059063.AUD","LU0058720904.USD","LU0868494617.USD","LU2456880835.USD","LU0708994859.HKD","IBBQ","LU2242646821.SGD","LU0289739699.SGD","LU0432979614.USD","LU1829250122.USD","IBB","LU2236285917.USD","IE00B2B36J28.USD","PBE","LU2237443622.USD","LU0029864427.USD","BK4139","BK4568","BK4534","BK4585","LU2237443382.USD","LU1267930573.SGD","LU2462157665.USD","LU2089984988.USD","TBXU","SG9999001440.SGD","AZN","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666309213","title":"安進-阿斯利康肺癌聯合用藥在後期臨床試驗中顯著提升生存率","url":"https://stock-news.laohu8.com/highlight/detail?id=2666309213","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666309213?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:39","pubTimestamp":1788921579,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1023059063.AUD","IBBJ","IBBQ","AMGN","LU0889565916.HKD","BK4588","LU0320765992.SGD","IBB","LU0868494617.USD","LU0058720904.USD","PSYK","BK4139","PBE","BK4533","BIB","IE0002141913.USD","IE00B4R5TH58.HKD","LU1983299246.USD","IE0009355771.USD","BK4566","LU0109394709.USD","BK4581","SG9999001440.SGD","LU1057294990.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU2242646821.SGD","LU2468319806.SGD","PJP","LU1571399168.USD","TBXU","BBH","LU2242652126.USD","LU2089984988.USD","IE00BFTCPJ56.SGD","LU1061106388.HKD","BK4585","IE00B2B36J28.USD","MDTX","IE00BJJMRZ35.SGD","BK4599","LU2112291526.USD","LU0122379950.USD","BK4534","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112638879","title":"市場風向標：安進股價遭受重創","url":"https://stock-news.laohu8.com/highlight/detail?id=1112638879","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112638879?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 05:35","pubTimestamp":1788903338,"startTime":"0","endTime":"0","summary":"“这对安进而言，堪称最糟糕的结局。”——巴克莱分析师艾米丽·菲尔德如此评价。此前，诺华制药公布了其心脏病药物令人失望的试验结果，这一披露不仅让诺华自身承压，更给安进旗下一款重磅药物蒙上了厚厚的阴影。","market":"us","thumbnail":"https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e5b05f9c7e258c0791b0ff14e4bfadad"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1023059063.AUD","LU0868494617.USD","PBE","LU1983299246.USD","IE00B4R5TH58.HKD","LU2112291526.USD","BK4534","IBBQ","LU0289739699.SGD","LU0320765992.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","AMGN","IE00BJJMRZ35.SGD","LU1061106388.HKD","IE00BJT1NW94.SGD","LU0889565916.HKD","LU2242646821.SGD","IBB","LU1057294990.SGD","IE0009355771.USD","BIB","IE0002141913.USD","LU2089984988.USD","PJP","BK4581","SG9999001440.SGD","BK4599","BBH","TBXU","BK4566","BK4533","LU2242652126.USD","BK4585","LU2468319806.SGD","LU0058720904.USD","LU1571399168.USD","LU0109394709.USD","LU0122379950.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136308873","title":"Assembly Biosciences有望獲得高達2.8億美元里程碑付款及美國境外特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1136308873","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136308873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 04:02","pubTimestamp":1788897732,"startTime":"0","endTime":"0","summary":"Assembly Biosciences公司日前披露，其在海外市场具备资格获取最高达2.8亿美元的里程碑款项，外加相应特许权使用费收入。据悉，这家生物科技企业所预期的资金流入将源自美国以外地区。对Assembly Biosciences而言，这笔潜在收入不仅反映其管线资产的外部合作价值，也可能为其后续研发投入提供坚实支撑。市场人士认为，此类非美国市场的收益结构有助于分散地域风险，增强公司财务韧性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIB","LU1934455194.USD","TMED","LU2087621335.USD","LU1430594728.SGD","LU1778281490.HKD","LU0882574055.USD","LU0965509101.SGD","BK4583","IE00BZ1G4Q59.USD","LU1037948897.HKD","TBXU","IE0002270589.USD","IE00B3T34201.USD","LU0861579265.USD","LU0114720955.EUR","BK4139","IBBQ","LU0823416689.USD","LU0965509010.AUD","LU1066051498.USD","LU2089984988.USD","LU2357627491.SGD","LU0889565916.HKD","LU1674673428.USD","LU0859254822.USD","LU0289739699.SGD","LU0965508806.USD","LU1061106388.HKD","LU1674673691.USD","LU1934455277.USD","LU1839511570.USD","LU1023059063.AUD","BK4585","LU1571399168.USD","BK4578","LU1934455863.HKD","IE00BSNM7G36.USD","LU2324357040.USD","IE00B19Z3B42.SGD","LU0965509283.SGD","IE00B19Z3581.USD","BK4532","IE00BKVL7J92.USD","BK4566","LU1037948541.HKD","SG9999015945.SGD","BBH","LU0320765992.SGD","LU2112291526.USD","BK4568","LU1066053197.SGD","IE00B7SZLL34.SGD","LU0234570918.USD","SG9999015986.USD","LU1057294990.SGD","LU1585245621.USD","LU2468319806.SGD","LU0058720904.USD","LU0122379950.USD","MEDI","BK4588","GILD","BMED","BK4550","IBB","SG9999015952.SGD","SG9999015978.USD","ASMB","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}